Date:1/17/2008

cal and clinical development of our products; the ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the ability to complete and maintain corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; the competitive environment and impact of technological change; and the continued availability of capital to finance our activities. Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this report to reflect future results, events or developments.

-------------------------

(1) Description and statistics taken from Canadian Association of Cardiac

Rehabilitation website found at: http://www.cacr.ca; Paus Jenssen,

L. Erik, Atrial Fibrillation Following Coronary Artery Bypass Grafting.

Canadian Association of Cardiac Rehabilitation (CACR) newsletter:

http://www.cacr.ca/news/news_0209.htm

(2) Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE,

Henderson WG, et al. Atrial fibrillation after cardiac surgery: a major

morbid event? Ann Surg 1997;226:501-11.

(3) Aranski SF, ShawDP, Adams DH, Rizzo RJ, Couper GS, VanderVliet

M. Predictors of atrial fibrillation after coronary artery surgery.

Current trends and impact on hospital resources.

Circulation 1996;94:390-7.

CONTACT: Angiotech Contacts: Jodi Regts, Angiotech Pharmaceuticals, Inc., (6
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
2. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
3. Angiotech to participate in RBC 2007 Healthcare Conference
4. Angiotech to participate in Bank of America 2007 Credit Conference
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
8. Angiotech to participate in UBS Global Life Sciences Conference
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line